Sarepta Therapeutics (SRPT) Gains Into Equity Pricing

September 22, 2016 11:42 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Sarepta Therapeutics (NASDAQ: SRPT), which has a pending $225M equity pricing, continues to surge higher. Shares are up 6.7% to $60. The stock is now up 120% since announcing FDA approval.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Equity Offerings, Trader Talk

Add Your Comment